Novartis announced results from its Phase 3 EXIST-1 study of Afinitor (everolimus) for the treatment of patients with subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC). EXIST-1 (EXamining everolimus In a Study of TSC) is a randomized, placebo-controlled, double-blind, parallel-group, international, multicenter study examining the efficacy and safety of everolimus vs. placebo for the treatment of patients with SEGA associated with TSC. EXIST-1 trial met its primary endpoint of SEGA response rate, with 35% of patients (27/78) receiving everolimus experiencing a 50% or greater reduction in SEGA volume relative to baseline vs. 0% of patients on placebo (P<0.0001).
Afinitor is currently approved in the U.S. to treat patients with SEGA associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical intervention.
For more information call (888) NOW-NOVA or visit www.us.novartis.com.